CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan) [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Vanrafia ™ (atrasentan), for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and are at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) =1.5 g/g. Vanrafia™ is a once-daily, non-steroidal, oral therapy that can be added onto supportive care, including a renin-angiotensin system (RAS) inhibitor with or without a sodium-glucose co-transporter-2 (SGLT2) inhibitor. Vanrafia™ was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo. “CareMed is grateful for the opportunity to become a specialty pharmacy provider for Vanrafia ™ ,” said
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Swiss Agree to Tariff Negotiations With Trump Administration [Yahoo! Finance]Yahoo! Finance
- Why Novartis (NVS) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Roche, answering tariff threat, pledges $50B to US drug production [Yahoo! Finance]Yahoo! Finance
- Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/25 - Beat
NVS
Sec Filings
- 4/3/25 - Form 6-K
- 3/28/25 - Form 6-K
- 1/31/25 - Form 6-K
- NVS's page on the SEC website